The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2022 | Current treatment strategies KRASG12C–mutated NSCLC
The KRAS p.G12C mutation is the most frequently observed mutation in metastatic non-small cell lung cancer (NSCLC) and has resulted in the creation of multiple targeted therapies. Liza Villaruz, MD, University of Pittsburgh, Pittsburgh, PA, provides an overview of current KRASG12C inhibitors, including adagrasib and sotorasib. Adagrasib has demonstrated promising results in previously treated patients as well as in untreated patients with brain metastases. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.
